ClinicalTrials.gov
ClinicalTrials.gov Menu

Almonds and Diabetes Management

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01161030
Recruitment Status : Completed
First Posted : July 13, 2010
Last Update Posted : July 13, 2010
Sponsor:
Information provided by:
Arizona State University

Brief Summary:

This trial examined the impact of acute and chronic almond ingestion on indicators of glucose control (postprandial glycemia and hemoglobin A1c). Hypotheses:

  1. Almonds will stimulate the secretion of GLP-1 in healthy adults and in adults with T2D The investigators were not able to demonstrate a relationship between GLP-1 secretion and almond consumption. Individuals with T2D were characterized with significantly greater GLP-1 secretion than the non-diabetic control subjects.
  2. Acute ingestion of almonds will decrease the postprandial glycemia and insulinemic responses in healthy controls and in individuals with T2D The investigators data support the hypothesis: almond consumption by individuals with T2D did attenuate postprandial glycemia; however, almond consumption did not alter glycemia in non-diabetic control subjects
  3. Chronic almond ingestion for 12 weeks will reduce fasting glucose (FG) and A1c concentrations in individuals with T2D The investigators data demonstrated modest beneficial effect of almond consumption on A1c in individuals with T2D. Almond consumption was also associated with modest weight loss as compared to the control treatment (low fat cheese sticks).

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Other: almonds Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Almond Ingestion at Meal-time Reduces Postprandial Glycemia and Chronic Ingestion Reduces Hemoglobin A1c in Individuals With Well-controlled Type 2 Diabetes
Study Start Date : August 2008
Actual Primary Completion Date : June 2009
Actual Study Completion Date : November 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: almonds Other: almonds




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 12 subjects with diagnosed T2D for at least 1 year and 12 healthy individuals without T2D will be recruited for the acute almond trial.
  • 24 subjects with diagnosed T2D for at least 1 year will be recruited for the chronic almond trial.
  • Subjects from the campus population and nearby communities will be recruited to participate in these trials.
  • Men and women must be willing to comply with the experimental protocol including the restriction of nut consumption:

    • subjects recruited for the acute almond study must agree not to consume any nuts or nut butters for 1-week prior to and during the 2-week trial
    • participants in the chronic almond study must agree not to consume nuts or nut butters more than 2 times per week during the 12 week trial.
  • Participants must have a body mass index (BMI) from 20 to 35 kg/m2 and are aged 30 to 70 years.
  • Subjects with T2D may take oral hyperglycemic agents.

Exclusion Criteria:

  • Insulin use
  • History of a peanut allergy
  • Chronic or unresolved disease
  • Current smoking habit
  • Pregnant or lactating
  • Medication use that may impact incretin secretion. [Incretins are gastrointestinal hormones secreted at meal-time.]

Responsible Party: Carol Johnston, Arizona State University
ClinicalTrials.gov Identifier: NCT01161030     History of Changes
Other Study ID Numbers: almond1
First Posted: July 13, 2010    Key Record Dates
Last Update Posted: July 13, 2010
Last Verified: July 2010

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases